A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients With Chronic Hepatitis B Infection
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 26 Jun 2021 Results assessing the long-term efficacy and safety for TDF treatment through 4 years (192 weeks), presented at The International Liver Congress 2021.
- 01 Jun 2021 Planned End Date changed from 1 May 2029 to 1 Jul 2027.
- 12 Jun 2020 Planned End Date changed from 1 May 2020 to 1 May 2029.